The abstract is read at the publisher; the summary is JClub's.
Glioblastoma response to standard-of-care treatment is captured by the JARID2 Binding Site (JBS) axis, with responder subtypes defined by movement from primary to recurrent states.
- Why it matters: Directional transcriptional reprogramming after treatment is observed but cannot be predicted from primary tumours, limiting ability to anticipate adaptive ecosystem shifts.
- What they did: Using independent longitudinal bulk and single-cell datasets, the study positions tumours and cells along the JBS axis via JBS gene expression and links axis movement to responder subtype states.
- The result: Recurrent tumours polarise toward opposite ends of the JBS axis, with microenvironment composition changes driving adaptive transcriptional responses more than chemoradiation alone, implicating JARID2-associated Polycomb regulation as a vulnerability.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.